 |
|
Preclinical anti-cancer effects
1. In mice 3LL-HH tumour and HCR-25 human colon carcinoma xenograft: disappearance of liver metastases. In B-16 melanoma: decrease in the number of liver and lung metastatic foci. In rat nephroblastoma: simultaneous use of Avemar and vitamin C decreased the growth of the primary tumour.
2. The combined use of Avemar with cytostatics:
in mouse C-38 colorectal carcinoma: synergism between 5-fluoro-uracyl (5-FU) and Avemar. In B-16 melanoma: synergism between DTIC and Avemar.
|
 |
|
 |
